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Conditionally replicating adenoviruses (CRAds) represent a promising class of novel anticancer agents that
are used for virotherapy. The E1A24 mutation-based viruses, Ad5-24 [CRAd(E3); E3 region deleted] and
infectivity-enhanced Ad5-24RGD [CRAd(E3)] have been shown to potently eradicate tumor cells. The
presence of the E3 region in the latter virus is known to improve cell killing that can be attributed to the
presence of the oncolysis-enhancing Ad death protein. The more precise mechanism by which CRAds kill tumor
cells is unclear, and the role of the host cell apoptotic machinery in this process has been addressed only in a
limited way. Here, we examine the role of several major apoptotic pathways in the CRAd-induced killing of non-
small-cell lung cancer H460 cells. As expected, CRAd(E3) was more potent than CRAd(E3). No evidence
for the involvement of the p53-Bax apoptotic pathway was found. Western blot analyses demonstrated strong
suppression of p53 expression and unchanged Bax levels during viral replication, and stable overexpression of
human papillomavirus type 16-E6 in H460 cells did not affect killing by both CRAds. CRAd activity was also
not hampered by stable overexpression of anti-apoptotic Bcl2 or BclXL, and endogenous Bcl2/BclXL protein
levels remained constant during the oncolytic cycle. Some evidence for caspase processing was obtained at late
time points after infection; however, the inhibition of caspases by the X-linked inhibitor of apoptosis protein
overexpression or cotreatment with zVAD-fmk did not inhibit CRAd-dependent cell death. Analyses of several
apoptotic features revealed no evidence for nuclear fragmentation or DNA laddering, although phosphatidyl-
serine externalization was detected. We conclude that despite the known apoptosis-modulating abilities of in-
dividual Ad proteins, Ad5-24-based CRAds trigger necrosis-like cell death. In addition, we propose that dereg-
ulated apoptosis in cancer cells, a possible drug resistance mechanism, provides no barrier for CRAd efficacy.
Conditionally replicating adenoviruses (CRAds) represent a
promising class of biologic agents designed to selectively rep-
licate in and lyse cancer cells, also known as virotherapy (for
reviews, see references 2, 23, and 37). Tumor specificity of
CRAds has been achieved by modifying a viral gene(s) impor-
tant for efficient viral replication in normal cells but not in
tumor cells that possess complementing genetic defects.
Two types of CRAds can be distinguished, in which either
the adenoviral genome is modified by a specific mutation or
deletion or tumor-specific promoters are inserted to drive the
expression of essential viral genes. For example, Ad5-24 con-
tains a partial deletion in the CR2 domain of the pRb-binding
protein E1A (dl922-947) that is complemented in pRb-deficient
tumor cells (13). An integrin-directed infectivity-enhanced
variant, CRAd24RGD, which is currently being evaluated in
clinical trials, demonstrated effective killing of different cancer
cells in vitro and in vivo (3, 29, 46, 47).
In animal studies and in the clinic, CRAds appear to be safe
and well tolerated; however, their antitumor activity as a single
agent is modest, and improvement of the therapy is required
(14, 24, 40). Strategies currently explored to enhance the effi-
cacy of these agents include the combined use of CRAds with
conventional therapies and the generation of armed CRAds
containing cytotoxic payloads. In this respect, the possibility
that interactions between the viral genome and host cell factors
will determine adenoviral oncolytic efficacy has been left rela-
tively unexplored (28) for wild-type Ad (wtAd) and has not
been addressed for CRAd24 variants. Ads normally infect
cells of the respiratory tract; however, they are redirected in
virotherapy to infect and kill tumor cells. Tumor cells are likely
to possess intrinsic genetic differences compared to normal
host cells that may also exist among different tumor types,
which could either facilitate or hamper CRAd replication and
cell killing. Such mechanisms may provide an explanation for
observed discrepancies in CRAd efficacy in addition to the
known distinct infection efficiencies.
Apoptosis is a specific form of programmed cell death
(PCD) that is characterized by several morphological changes
that are most prominently visible in the nucleus, including
chromosome condensation and nuclear shrinkage and frag-
mentation. The caspases, members of the family of aspartic
acid-specific cysteine-proteases, are the executioners of apo-
ptosis and essential for the disassembly of the cell (for reviews,
see references 9, 20, 45, and 48). Two main apoptotic pathways
have been identified that induce caspase-dependent apoptosis
upon exposure to various stimuli. The intrinsic pathway can be
triggered by cytotoxic agents, for example, and involves the
destabilization of mitochondria leading to activation of cas-
pase-9. The extrinsic pathway is initiated via death receptors,
such as Fas/CD95, that activate caspase-8. Both caspase-8 and
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caspase-9 can activate the downstream or executor caspase-3,
-6, and -7. The activity of caspases can be regulated by mem-
bers of the inhibitor of apoptosis (IAP) family, such as X-
linked IAP (XIAP) (54). The Bcl-2 family of proteins comprise
antiapoptotic and proapoptotic members that are key regula-
tors of the mitochondrial pathway (1, 27, 41). Proapoptotic
members, including Bax, can induce mitochondrial instability
leading to the release of cofactors that allow the activation of
caspase-9 assembled in the apoptosome. The activation of the
basic apoptotic machinery as briefly outlined above is consid-
ered to largely determine the success of cancer therapies, and
obstruction of this apoptotic machinery in cancer cells may
cause resistance to treatment.
Ads have a rather complex infrastructure in which the viral
genes produce numerous proteins that prevent the death of
infected cells early after infection and other proteins that favor
cell death at later stages (6, 28, 33, 38, 42, 52). Several viral
encoded proapoptotic and antiapoptotic proteins are known to
maintain temporal control of the Ad on the host cell.
Most notably, E1B-19KD (an Ad Bcl2 homologue), E1B-
55KD in complex with E4orf6, and the E3-10.4KD and E3-
14.5KD proteins, which are encoded by early transcribed genes,
act as antiapoptotic proteins and are responsible for the preven-
tion of premature oncolysis or cause immune suppression, while
E1A-12S, E1A-13S, E4orf4, and E3-11.6KD (Ad death protein
[ADP]) act as proapoptotic proteins when tested individually.
In addition, the mechanism responsible for the oncolysis-en-
hancing effect of ADP is largely unknown (32, 50). Thus, dur-
ing Ad infection, the viral proteins act in concert with several
host cell-encoded key apoptotic regulators in a sort of cell death-
balancing act, leading to the timed delay of cell death and allow-
ing the efficient replication and generation of viral offspring.
Despite the known apoptosis-regulatory function of individ-
ual Ad genes, it is currently unknown whether the disruption of
cancer cells at the last stage of CRAd infection, named oncol-
ysis, employs the basic apoptotic machinery of the host cell.
To explore this, we set out to investigate the role of the basic
apoptotic machinery during the CRAd24-induced killing of
non-small-cell lung cancer (NSCLC) H460 cells. The involve-
ment of several main apoptotic pathways was studied, in-
cluding p53, Bcl2, and caspase-mediated cell death, and the
morphological and biochemical features associated with
CRAd24-induced cell death were examined. Interestingly,
CRAd-induced cell death can be classified as a necrosis-like
PCD that bypasses the apoptotic machinery of the host cell ir-
respective of the presence or absence of the E3 region (ADP),
suggesting that deregulated apoptotic pathways in cancer are un-
likely to have a negative impact on CRAd-induced cell killing.
MATERIALS AND METHODS
Cell culture and treatment. The human NSCLC NCI H460 parental cell line
(p53 Rb wt p16INK4) (22); the previously generated derivatives H460Bcl2,
H460BclXL, and H460XIAP; these derivatives’ empty vector controls H460\
PEFPGK3 and H460\pcDNA3 (11); and H460–human papillomavirus type 16
(HPV16)-E6 (designated H460HPV16-E6) (53) were cultured in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine serum (Invitro-
gen, Breda, The Netherlands), 50 IU of penicillin/ml, 50 g of streptomycin/ml,
and 1 g of puromycin/ml or 200 g of Geneticin/ml, depending on the cell line,
and grown at 37°C in a humidified air with 5% CO2. The cells were tested
routinely for the absence of mycoplasma before use, and overexpression of Bcl2,
BclXL, and XIAP proteins was confirmed by immunohistochemistry prior to use
in the experiments. For apoptosis activation, cells were treated with 25 ng of
anti-Fas activating antibody (clone CH11; Upstate Biotechnology, Inc., Lake
Placid, N.Y.)/ml together with 0.5 g of cycloheximide (CHX; Sigma, St. Louis,
Mo.)/ml for 16 h or with 14 M cisplatin (CDDP; Bristol-Myers Squibb, Woer-
den, The Netherlands) for 3 days. Caspase activation was inhibited by exposure
of cells to the pan-caspase inhibitor zVAD-fmk at 100 M (Enzyme Systems
Products, Livermore, Calif.).
CRAd infection and viability measurement. Ad24 [CRAd(E3)] and
Ad24RGD [CRAd(E3)] harbor a 24-bp deletion in the pRb-binding CR2
domain in the E1A region; the latter contains the E3 region (E3) and harbors
an RGD motif cloned in the fiber knob that enhances infectivity in a wide range
of cancer cells (47). Cells cultured to near-confluence in 96-well plates were
incubated with different multiplicities of infection (MOIs) (0.001 to 100 PFU/
cell) of CRAd(E3) or CRAd(E3) in growth medium (50 l/well) at 37°C.
Two hours postinfection, another volume of virus-free medium was added. Cell
viability was measured within 7 days postinfection with WST-1 reagent (Roche
Diagnostics, Mannheim, Germany). Briefly, the culture medium was removed
and replaced by 100 l of 10% WST-1 in culture medium.
Depending on cell type and density, the formation of the formazan dye was
allowed to proceed for 30 to 60 min at 37°C, and the A450 was measured with a
model 550 microplate reader (Bio-Rad Laboratories, Hercules, Calif.). The
percentage of growth (WST-1 conversion) of treated cells was expressed as a
percentage of the conversion by uninfected control cells after subtraction of
background values of WST-1 incubated in the absence of cells. Alternatively, the
oncolytic potential of the CRAds in relation to cell viability was determined by
crystal violet staining. Cells were washed with phosphate-buffered saline (PBS)
(10.9 mM Na2HPO4, 1.8 mM NaH2PO4, 8.2 g of NaCl/liter), fixed for 10 min at
room temperature (RT) in 4% (vol/vol) formaldehyde in PBS, and stained using
10 g of crystal violet dye/liter in 70% (vol/vol) ethanol for 20 min at RT. After being
washed several times with water, the culture plates were air dried prior to imaging.
Western blotting. Cells were lysed at 24, 48m and 72 h postinfection as
indicated in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% sodium
dodecyl sulfate, 0.5% sodium deoxycholate [Fluka Biochemika, Buchs, Switzer-
land], 1% Igepal [NP-40; Sigma], and 1 mM PEFA block protease inhibitors
mixture [Roche Diagnostics]) on ice and stored at 80°C for further use. After
determining sample protein concentrations by the bicinchoninic acid protein
assay reagent kit (Pierce Biotechnology, Rockfort, Ill.), 20 g of each sample was
separated on a sodium dodecyl sulfate–12.5%polyacrylamide gel electrophoresis
gel. Thereafter, the proteins were blotted on a polyvinylidene difluoride mem-
brane (Bio-Rad). The membrane was rinsed in blocking solution containing 5%
nonfat milk in TBST (0.1% Tween 20, 150 mM NaCl, and 10 mM Tris-HCl [pH
8]). The following first antibodies, dissolved in 5% bovine serum albumin–TBST,
were used: anti-human p53 monoclonal antibody (MAb) (dilution 1:1,000;
DAKO, Glostrup, Denmark), anti-Bax MAb (dilution 1:250; BD Transduction
Laboratories, Sparks, Md.), rabbit polyclonal anti-BclXL (dilution 1:250; DAKO
Diagnostics, Mississauga, Ontario, Canada), anti-Bcl2 MAb (dilution 1:2,000;
DAKO), rabbit polyclonal anti-poly(ADP-ribose) polymerase (PARP) (dilution
1:2000; Roche, Almere, The Netherlands), anti-caspase-8 MAb (dilution 1:2,000;
Immunotech, Prague, Czech Republic), rabbit anti-caspase-9 (dilution 1:2,000;
PharMingen, San Diego, Calif.), anti-caspase-3 MAb (dilution 1:1,000; BD
Transduction Laboratories), and anti--actin MAb (dilution 1:7,500; Sigma).
After incubation for 1 to 2 h with the primary antibody and washing in TBST,
the blots were incubated with peroxidase-conjugated goat anti-rabbit (dilution
1:5,000) or rabbit anti-mouse (dilution 1:2,000) IgG secondary antibody (DAKO).
For chemoluminescence detection, blots were immersed in enhanced chemilu-
minescence solution and exposed to hyperfilm (Amersham Pharmacia UK, Ltd.,
Buckinghamshire, United Kingdom).
Apoptosis detection assays. For DNA fragmentation analyses, 5  105 cells
were harvested 72 h postinfection, and DNA was extracted as described previ-
ously (12). In brief, cells were pelleted and lysed with 30 l of lysis buffer
containing 20 mM EDTA, 100 mM Tris (pH 8.0), 0.8% sodium lauryl sarcosi-
nate, and 5 mg of proteinase K/ml. After 2 h of incubation at 50°C, 0.2 mg of
RNase A/ml was added, and the lysate was incubated for another 30 min at 37°C,
prior to electrophoresis on a 1.5% agarose gel containing ethidium bromide (0.2
g/ml). Nuclear morphology was examined in treated or untreated cells cultured
on coverslips that were washed once with PBS before incubation in the fixative
(3.7% formaldehyde in PBS) for 30 min at RT, stained with Hoechst 33342
(Sigma) for 1 h at RT, and mounted with Vectashield (Vector Laboratories Inc.,
Burlingame, Calif.). Stained nuclei were visualized at a 40 magnification under
UV light. Phosphatidylserine (PS) externalization was determined after exposure
to the phospholipid-binding protein Annexin V, according to the manufacturer’s
protocol (Roche). In brief, cells cultured on coverslips were incubated with
fluorescein-labeled Annexin V and propidium iodide (PI)-containing buffer
(Roche) for 15 min at RT. Annexin V and PI staining were visualized at a
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63 magnification under blue and green light, respectively, with an inverted
DMIRB/E fluorescence microscope (Leica, Heidelberg, Germany) using Leica
Q500MC Quantimet software, version 1.01 (Leica Cambridge, Ltd., Cambridge,
United Kingdom).
RESULTS
CRAd-induced killing of H460 cells. To determine the mode
of cell death induced by CRAds, we used two variants: E3
region-deleted virus, CRAd(E3), and CRAd(E3), contain-
ing the E3 region and possessing integrin-mediated enhanced
infectivity (29). In this study, we compared the mechanism of
cell killing by these two CRAds, assuming that RGD targeting
only leads to enhanced infection efficiency without affecting
the underlying mechanism of cell killing. For a model system,
we employed the NSCLC H460 cell line. First, we assessed the
oncolytic effect of the CRAds in H460 cells by determining cell
viability by WST-1 (Fig. 1A) and crystal violet staining assays
(Fig. 1B) at 5 and 11 days, respectively, after infection with
different MOIs. As expected, both viruses showed MOI-depen-
dent toxicity with CRAd(E3) that was more potent than with
CRAd(E3) in killing H460 cells; 50% inhibitory concentra-
tion values were 3.5 and 30 PFU/cell, respectively.
p53-Independent cell killing by CRAds in H460 cells. To
investigate the role of p53 in mediating cell death triggered by
CRAds in H460 cells, the expression of p53 was examined by
Western blotting in extracts derived from CRAd-infected cells
that were harvested at different time points after infection (Fig.
2A). The levels of p53 progressively decreased within 2 days
after CRAd(E3) infection, which can be attributed to E1B-
55KD-mediated degradation (18, 36). The presence of the E3
region accelerated the reduction in p53 levels that may also be
caused by accelerated internalization via the integrin-targeting
motif RGD. The expression of the p53-inducible proapoptotic
Bcl2 family member Bax was also studied, revealing a time-
dependent decrease after CRAd(E3) infection. The pres-
ence of the E3 region augmented CRAd-induced Bax reduc-
tion at 24 h postinfection, and levels remained low at later time
points. As a control, H460 cells were treated with CDDP,
which resulted in the induction of Bax and a less appreciable
accumulation of p53 (Fig. 2A), which is in line with the ex-
pected activation of a p53-dependent route to apoptotic cell
death. Activation of a p53-independent death receptor path-
way with an agonistic Ab directed against the Fas receptor
caused a decrease in the levels of p53 and Bax.
To further assess the role of p53 in CRAd-induced cell
death, H460 cells stably transfected with HPV16-E6, which
possess reduced levels of p53 caused by HPV16-E6-mediated
degradation of p53 (Fig. 2B), were infected with different
MOIs of CRAd(E3). Cell viability was measured at 7 days
postinfection and was compared to CRAd toxicity in empty
vector-transfected p53-expressing control cells (H460-neo)
(Fig. 2C). The E6-dependent inhibition of p53 did not influ-
ence the oncolytic effect of this CRAd. Together, these data
indicate that the cell killing effect of both tested CRAds is not
dependent on the activation of p53-dependent apoptosis.
Cell death induced by CRAds is triggered independent of
caspases and Bcl2. Next, the contribution of the basic apopto-
tic machinery to CRAd-induced cell death was evaluated more
directly. H460 cells were infected with the two CRAds at an
MOI of 25, and the processing of procaspases-9, -8, and -3 and
the caspase substrate PARP was determined by Western blot-
ting at various days postinfection. Figure 3A shows that both
CRAds produced some PARP cleavage at 24 and 48 h after
infection, followed by a decrease in both unprocessed PARP
(116 kDa) and cleaved PARP (89 kDa) at 3 days postinfection.
The activation of caspases was studied by monitoring the de-
crease in the band representing the procaspase form that is
indicative for caspase activation. Apart from a small decrease
in the procaspase bands at 3 days postinfection, there is no
clear indication of caspase processing in contrast to the strong
activation observed during Fas-induced apoptosis (Fig. 3A)
that was used as a positive control for death receptor and
caspase-dependent apoptosis. Subsequently, the involvement
of the anti-apoptotic Bcl2 family members Bcl2 and BclXL,
key regulators of the mitochondrial apoptotic pathway, was
studied during CRAd-induced cell death. In Western blotting
experiments, the expression levels of Bcl2 and BclXL did not
decrease (Fig. 3B); together with the above-demonstrated lack
of increase in Bax levels (Fig. 1A), these findings are indicative
for the lack of participation of the mitochondrial pathway in
mediating cell killing by these CRAds.
To further test the role of caspases and Bcl2 in CRAd-
triggered cell death, we used a panel of H460-derived stable
transfectants overexpressing Bcl2, BclXL, and XIAP, the latter
an inhibitor of caspase-9- and caspase-3-dependent apoptosis
(54). These cell lines have been generated previously and
shown to be potent in inhibiting mitochondria- and caspase-
dependent apoptosis in H460 cells (11). The stable transfec-
FIG. 1. Infectivity-enhanced Ad24RGD[CRAd(E3)] is more
potent in killing H460 cells than Ad24[CRAD(E3)]. The viability of
H460 cells was determined by the WST-1 assay, with three experi-
ments. Data show means  standard deviation (A) and crystal violet
staining (B) at 5 and 11 days postinfection, at different MOIs.
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tants were tested for their sensitivity to the oncolytic effect of
CRAd(E3) when compared to parental H460 cells and vec-
tor-transfected control H460 cells (Fig. 3C, H460\PEFPGK3
and H460\pcDNA3). No protection was observed by the over-
expression of Bcl2, BcXl, or XIAP, and similar results were
found for CRAd(E3) (data not shown).
As a final test to examine the possible involvement of cas-
pases in CRAd-induced cell death, H460 cells were cotreated
with the broad caspase inhibitor zVAD-fmk at a concentration
of 100 M, which completely protected against the apoptotic
effect of FasL plus CHX (FasLCHX) (Fig. 3D). In line with
the above, CRAd activity was not suppressed in a detectable
way by zVAD-fmk administration, further confirming that cas-
pases are not involved in the execution of CRAd-induced cell
death.
Analyses of biochemical and morphological features of apo-
ptosis in H460 cells undergoing CRAd-induced cell death.
Finally, CRAd-dependent changes in several parameters of
apoptosis were examined. Nuclear morphology was studied by
staining H460 cells with Hoechst 33342 at 3 days after infection
with both CRAds at an MOI of 25 in the presence or absence
of 100 M zVAD-fmk to assess caspase-dependent phenom-
ena (Fig. 4A). Regardless of the presence of the E3 region,
both CRAds seemed to cause some swelling of the nuclei, and
regions with more intense staining (i.e., a speckled appear-
ance) were observed that were not affected by zVAD-fmk
treatment. In contrast, FasLCHX exposure clearly induced
chromosome condensation, nuclear shrinkage, and/or frag-
mentation that could be reverted to normal by cotreatment with
100 M zVAD-fmk, indicative of caspase-dependent apoptosis.
DNA fragmentation assays were also performed at 3 days
after infection with both CRAds. Contrary to the pronounced
DNA fragmentation found in FasLCHX-positive control
cells, no DNA fragmentation was observed in CRAd(E3)- or
CRAd(E3)-infected cells (Fig. 4B). Caspase inhibition by
100 M zVAD-fmk completely protected against FasLCHX-
induced DNA laddering.
The last marker of apoptosis that we examined was the loss
of phospholipid symmetry and externalization of PS residues in
cells with an intact membrane that is indicative for apoptosis
(10, 21) and which was determined by AnnexinV staining
within 2 days after CRAd infection. The cells were costained
with PI in order to discriminate apoptotic cells (Annexin V
positive and PI negative) from necrotic ones (Annexin V and
PI positive due to membrane permeabilization). The results
obtained were similar for both CRAds and are only shown for
CRAd(E3), which induced a somewhat more rapid PS exter-
nalization than CRAd(E3), in line with its faster rate of
oncolysis. Untreated cells remained negative for Annexin V
staining for the duration of the experiment (Fig. 4C). The
majority of CRAd-infected cells showed Annexin V-positive
membrane staining in the absence of PI staining. In a small
FIG. 2. The p53-Bax apoptotic pathway is not involved in CRAd(E3)- or CRAd(E3)-induced cell killing of H460 cells. Western blot analyses of
p53 and Bax expression in H460 cells infected with CRAd(E3) or CRAd(E3) at an MOI of 25 at different time points after infection are shown.
As a control, H460 cells were treated with CDDP or with FasLCHX (Fas). -Actin serves as a control for loading (A). The reduced expression
level of p53 in stable HPV16-E6-overexpressing H460 cells (H460-E6) was confirmed (B). CRAd-induced cell killing at different MOIs was
examined in H460-E6 cells and in empty vector-transfected control H460 cells (H460-neo) at 7 days after infection by WST-1 assays. The results
obtained for CRAd(E3) are shown and were similar to those for CRAd(E3) (C). Values are means  standard deviation of three experiments.
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portion of CRAd-infected cells, PS externalization was accom-
panied by PI staining; this may represent a minority of cells
that became leaky during virus propagation. Coexposure with
zVAD-fmk did not alter the Annexin V staining pattern in the
infected cells. FasLCHX-treated cells displayed Annexin V-
positive and PI-negative cells, and PS exposure was completely
prevented by zVAD-fmk (Fig. 4C). This indicates that CRAds
trigger PS externalization via a caspase-independent mecha-
nism, in contrast to FasLCHX treatment, which induces cas-
pase-dependent PS exposure.
DISCUSSION
The eradication of cancer cells by gene therapy approaches
that are based on the molecular characteristics of cancer cells
provides a promising new therapeutic platform. In this respect,
CRAds represent rationally designed agents for the selective
FIG. 3. CRAd(E3)-induced cell death is not mediated by caspases and is not dependent on the activation of the mitochondrial apoptotic
pathway regulated by Bcl2. H460 cells were infected at an MOI of 25, and cell extracts were made at different times postinfection and subjected
to Western blotting. As a control, H460 cells were treated with agonistic Fas Abs in combination with CHX (Fas). (A) The expression levels of
unprocessed procaspase-9, -8, and -3 were assessed together with the cleavage of caspase substrate PARP. (B) Bcl2 and BclXL expression was also
determined. (C) CRAd(E3)-induced cell killing in H460-derived stable transfected cell lines overexpressing antiapoptotic Bcl2 and BclXL or the
caspase-inhibitor XIAP when compared to the empty vector controls H460\PEFPGK3 and H460\pcDNA3 was studied. Different MOIs were used,
and WST-1 activity was measured at 4 days postinfection. Similar results were obtained for CRAD(E3). (D) Cotreatment with the broad caspase
inhibitor zVAD-fmk failed to protect H460 cells from CRAd(E3)-induced cell death, whereas it was effective in protecting against apoptosis
induced by FasLCHX cells that served as a positive control. Values are means  standard deviation of three experiments.
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killing of cancer cells, while leaving normal cells intact. Despite
exciting laboratory results with CRAds, several practical ob-
stacles need to be overcome before virotherapy can fulfill its
goals in the clinic.
In this study, we focused on the possibility that the host cell
apoptotic machinery may either facilitate or suppress CRAd-
induced cell killing in cancer cells, as this may cause resistance
to CRAds and lead to intratumor variation in CRAd efficacy.
In various cellular and biochemical assays, we showed that
CRAd(E3) and CRAd(E3) kill H460 NSCLC cells inde-
pendent from the basic apoptotic machinery. At late time
points after infection, some evidence for procaspase processing
FIG. 4. Lack of apoptotic features in H460 cells undergoing cell death triggered by CRAd(E3) and CRAd(E3). (A) H460 cells were infected
with both CRAds at an MOI of 25 alone or in combination with 100 M zVAD-fmk for 2 days. As a control, cells were exposed for 16 h to
FasLCHX with or without zVAD-fmk. Nuclei were stained with Hoechst 33342 to visualize chromatin condensation, nuclear shrinkage, or
fragmentation that are markers for apoptosis by immunofluorescence microscopy. CRAd-infected cells did not display nuclear apoptotic features,
in contrast to FasCHX-exposed cells that show condensed and fragmented nuclei reversible by zVAD-fmk. (B) DNA fragmentation was also
analyzed, revealing no apoptotic DNA laddering in CRAd-infected cells, whereas FasLCHX treatment results in clear DNA smearing.
(C) Annexin V staining caused by PS externalization was examined 1 and 2 days postinfection and in FasLCHX-treated H460 cells with and
without zVAD-fmk. Cells were cotreated with PI to allow the distinction between Annexin V staining in the presence or absence of an intact
membrane detected by immunofluorescence microscopy; the phase-contrast image is also shown (Phase). A minor portion of CRAd-infected cells
were PI positive (indicated by arrows). Annexin V staining is caspase independent in CRAd-infected cells and caspase dependent when induced
by FasLCHX. Results are shown for CRAd(E3)-infected cells; similar findings were obtained for CRAd(E3)-infected cells.
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was found (Fig. 3); however, the pan-caspase-inhibitor zVAD-
fmk and overexpressed XIAP did not influence CRAd-medi-
ated H460 cell killing, indicating that the observed caspase
cleavage is a cophenomenon and not instrumental for CRAd
toxicity. In line with this, the small proportion of cleaved PARP
may reflect to some extent the apoptosis-regulatory activity of
the adenoviral proteins in preventing the cell from dying early
before completion of the reproductive viral cycle. Rather than
inducing PARP cleavage, PARP expression fades away at 3
days postinfection, which is suggestive of caspase-independent
cell death. The lack of effect of caspase inhibition by zVAD-
fmk on cell death triggered by these CRAds was also observed
in NSCLC A549 and SW1574 cells (unpublished data).
The apparent lack of involvement of the basic apoptotic
machinery in mediating CRAd-induced cell death was con-
firmed in H460 cells overexpressing Bcl2 or BclXL that failed
to protect against the oncolytic effect of CRAds. In this con-
text, the presence or absence of the E3 region did not affect the
mode of cell death, in agreement with the observed nonapo-
ptotic cell death induced by ADP (6, 50).
Previously, it has been speculated that ADP that is expressed
in large amounts at late stages after infection facilitates onco-
lyses in a stoichiometric manner by targeting the nuclear mem-
brane where it either binds and/or deactivates antiapoptotic
proteins like cellular Bcl2 or viral E1B-19KD or acts by dis-
rupting nuclear membrane (5, 15). Our data showing that ADP
did not engage the apoptotic machinery is more in favor with
the latter hypothesis that ADP mainly targets the nuclear
membrane rather than modulating antiapoptotic factors to en-
hance oncolysis.
The role of p53 in determining the oncolytic activity of
replicating Ads is somewhat controversial. After Ad infection,
p53 accumulates, which is counteracted by E1B-55KD together
with E4orf6, acting as E3 ubiquitin ligase, which complexes
with p53, resulting in its degradation and preventing p53-de-
pendent apoptosis. On one hand, it has been demonstrated
that p53 in a complex with E1B-55KD–E4orf6 is required for
efficient (rapid) oncolysis (8, 16) and that p53 overexpression
(19, 44, 51) enhances the oncolytic effect of CRAds; in other
studies, the presence or absence of functional p53 did not alter
replication and release of Ad (26). A possible drawback in
these latter studies is that tumor cell lines derived from distinct
sources were compared, which does not rule out the possibility
that other genetic differences apart from p53 status may influ-
ence Ad propagation. By using the isogenic cell lines H460 and
H460HPV16-E6, we sought to overcome this. Our experiments
with Ad24-based CRAd(E3) and CRAd(E3) did not show
an effect of overexpression of the p53-sequestering HPV16-E6
protein on CRAd-induced cell killing in H460 cells, which
supports the notion that p53 status does not influence CRAd-
induced cell death. Our results are in agreement with reports
of Harada and Berk (17) and others (18, 45), who showed
comparable adenoviral production (replication and release) in
cancer cells independent from p53 status, including in p53-null
NSCLC cell lines (e.g., H1299) and p53-wild-type counterparts
(17, 43). However, in our experiments we cannot rule out the
possibility that even in H460HPV16-E6 cells only a very small
portion of p53/E1B-55KD/E4orf6 is formed that is sufficient
for normal oncolysis. In this scenario, p53 triggers an as-yet-
unknown cell death mechanism that is distinct from classic
p53-dependent apoptosis via the intrinsic (mitochondrion-me-
diated) route. Yet we can rule out that the E1A mutation
specific to the Ad5-24-based viruses plays a role in rendering
CRAd(E3)- and CRAd(E3)-induced cell killing p53 inde-
pendent, since wtAd5 induces a similar p53-independent cell
killing in HPV16-E6-overexpressing H460 cells (data not shown).
Apart from addressing the role of the apoptotic machinery
in CRAd-induced cell death, we also monitored a panel of
morphological parameters that allows the more precise classi-
fication of the mode of cell death that can range from apopto-
sis to necrosis. Apoptosis, as a distinct PCD process, is mainly
characterized by a combination of hallmark morphological and
biochemical changes, including DNA fragmentation, chroma-
tin condensation, cytoplasmic shrinkage, and PS externaliza-
tion, which can be associated with molecular markers such as
the activation of caspases (20). More recently, it has been
reviewed that other types of PCD exist in which caspases are
not activated despite the presence of apoptotic features, such
as DNA fragmentation and chromatin condensation; this type
of PCD is named apoptosis-like PCD (31). In the absence of
chromatin condensation, this type of PCD is termed necrosis-
like PCD, which can still be associated with apoptotic markers
such as PS externalization. CRAd-induced oncolysis, regard-
less of the presence of the E3 region, was not associated with
apoptotic DNA fragmentation caused by internucleosomal
DNA cleavage (Fig. 4B). Nuclear staining revealed small ag-
gregates (speckled staining) spread in the nucleus of CRAd-
infected cells (Fig. 4A), which is difficult to assign either to
aggregates of Ad DNA or to irregular chromatin condensation.
By visual observation, CRAd infection seemed to increase the
size of the nucleus to some extent, in contrast to the nuclear
shrinkage and fragmentation observed with FasLCHX-
treated cells. Finally, Annexin V staining assays showed that
CRAd-induced cell death was associated with PS externaliza-
tion that could not be blocked by zVAD-fmk, in contrast to PS
exposure-induced by FasLCHX that was caspase dependent.
TABLE 1. Summary of apoptotic features found in H460 cells infected with Ad24-based CRAds and mode of cell death
Cellular and
molecular changes
Cell death Induced cell death
Apoptosis Apoptosis-like PCD Necrosis-like PCD Necrosis CRAds-induced oncolysis FasLCHX
Chromatin condensation     a 
DNA laddering  /    
Cytoplasmic shrinkage  / /   
PS exposure      
Caspase activation  / / /  
a Chromatin condensation occurs but is distinct from “apoptotic condensation” (see text).
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Regardless of the observed loss of membrane integrity in a
portion of CRAd-infected cells, PS exposure was the only
apoptotic marker found in this study. In Table 1, the results are
summarized whereby CRAd-induced phenomena are com-
pared to apoptosis induced by FasLCHX treatment and four
forms of cell death. It can be concluded that the detected
molecular and cellular features that characterize CRAd-
induced cell death rule out apoptotic or necrotic cell death
and that necrosis-like PCD fits CRAd(E3)- and
CRAd(E3)-induced cell death best, although this is inevita-
bly somewhat arbitrary.
The found lack of involvement of the basic apoptotic ma-
chinery in mediating CRAd(E3)- and CRAd(E3)-induced
cell death corresponds with previous data showing that wtAd
type 5 (wtAd5)-induced cell kill was not associated with DNA
fragmentation or the formation of apoptotic nuclei (35, 49)
and also indicates that the 24 mutation in E1A does not alter
these features. This is remarkable when considering the clear
apoptotic or antiapoptotic activities of the various character-
ized individual adenoviral proteins (reviewed in references 6,
38, and 52). For example, E1A13S-induced apoptosis is asso-
ciated with caspase-3 activation and PARP cleavage (4);
Lavoie and coworkers (30) showed that E4orf4-induced p53-
independent cell death was associated with loss of mitochon-
drial membrane potential and chromatin condensation but
without caspase-3 activation or PARP cleavage. However, as
we demonstrate here, when Ad proteins act in concert, the net
outcome is the activation of a caspase-independent mode of
cell death. This may be explained by assuming that Ad proteins
that trigger caspase-independent and nonclassical apoptotic
cell death dominate this process, such as the previously men-
tioned E4orf4 protein (7, 25). In the literature, cell death
induced by replicating Ads is often referred to as apoptosis,
which in light of this study is incorrect. It should be noted that
different assays are used in these studies to determine apopto-
sis that are not suitable for making the distinction between
apoptotic and nonapoptotic forms of cell death. More impor-
tantly, it should be realized that depending on the particular
combination of replicating Ad vector and host cell line used,
the outcome may vary. For example, the use of an Ad2-based
mutant that lacks E1B-19KD (a Bcl2 homologue) expression
was found to have an enhanced cytopathic effect in colon
cancer HCT116 cells with a functional Bax gene when com-
pared to non-Bax-expressing counterparts, which was inter-
preted as evidence for Bax contributing to Ad-induced apo-
ptosis (34). This finding may be true for a virus with a deleted
E1B-19KD gene in a Bax-positive background, but it is not
relevant for a CRAd expressing the Bax-inhibiting E1B-19KD
protein. Similarly, the concept that induction of cell death in
Ad-infected cancer cells may enhance progeny virus release
and spread has been shown for a particular combination of
host cells and Ad. Mi and coworkers (39) found that in HeLa
cells infected with Ad E1/E3-deleted viruses that overexpress
IB, which sensitizes cells for tumor necrosis factor 	 (TNF-
	)-induced apoptosis, the administration of TNF-	 after the
virion assembly stage enhanced viral release.
For the generation of more effective CRAds, interfering
with the early apoptosis-regulating properties of the Ad should
be avoided when possible, to prevent adverse effects on opti-
mal virus production. Correctly timed expression of proapo-
ptotic genes is therefore essential and can be achieved (for
example) by production from the E3 region, as reported for
TNF-	 (42). The expression of diffusible apoptosis-inducing
proteins could also have therapeutic benefit by their ability to
act at a distance from the infected cells, thereby circumventing
possible barriers in the tumor mass that may hinder virus
spread.
Our study indicates that deregulated apoptosis in cancer
cells will likely not oppose effective CRAd-induced cell death.
Their mechanism of tumor cell killing is therefore different
from conventional therapies in which apoptosis activation con-
tributes to cell death and may provide an explanation for the
potency of CRAds in killing chemo-resistant tumor cells. It
seems that during evolution, Ads evolved a mechanism for
disrupting the host cell at the final stage of the viral cycle that
does not require the activation of the basic apoptotic machin-
ery. Currently, we are attempting to identify pathways that are
involved in the activation of CRAd-induced cell death by em-
ploying microarray-based approaches. The elucidation of host
cell mechanisms that affect CRAd-dependent oncolysis will help
to identify CRAd-resistance mechanisms and allow the devel-
opment of rationalized strategies to circumvent such hurdles.
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